Posted by Michael Wonder on 17 Feb 2021
BeiGene announces U.S. FDA acceptance of supplemental new drug application for Brukinsa (zanubrutinib) in Waldenström’s macroglobulinaemia
17 February 2021 - BeiGene today announced that the U.S. FDA has accepted a supplemental new drug application for Brukinsa (zanubrutinib) for the treatment of adult patients with Waldenström’s macroglobulinaemia.
The Prescription Drug User Fee Act target action date is 18 October 2021.
